December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novavax, Inc. - Common Stock (NQ:NVAX)

8.550 -0.360 (-4.04%)
Streaming Delayed Price Updated: 3:10 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novavax, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
64 65 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Earnings Scheduled For February 28, 2024
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. 
Via Benzinga
Novavax's Earnings Outlook
 
Via Benzinga
Has Novavax Just Solved Its Biggest Problem?
The biotech company recently settled a dispute with a major customer. 
Via The Motley Fool
Beyond Meat, Viking Therapeutics, Novavax, Baidu, Tesla: Why These 5 Stocks Are On Investors' Radars Today
The U.S. indices were mixed with the S&P 500 rising by nearly 0.2% to 5,078.18 and the Dow Jones Industrial Average falling by 0.25% to 38,972.41. 
Via Benzinga
Topics Stocks
Exploring Stocks with High Short Interest: INBS, BLNK, BYND, NVAX, PLUG
Via AB Newswire
Topics Electric Vehicles
Novavax’s dispute resolution and upcoming earnings call
Novavax navigates legal settlements, earnings expectations, and competition, hoping their protein-based vaccines become a global health game-changer. 
Via MarketBeat
Topics Earnings
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Better Bull Market Buy: Novavax vs. Pfizer
Bull markets usually favor stocks with promising growth prospects. 
Via The Motley Fool
Where Will Novavax Be in 10 Years?
Without any windfalls on the horizon, times are dire for this biotech. 
Via The Motley Fool
Better Recovery Story Buy: Novavax vs. Teladoc
Both stocks have fallen more than 90% from their peak. 
Via The Motley Fool
Why Etsy Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Etsy, Inc. 
Via Benzinga
NICE Posts Upbeat Earnings, Joins FTI Consulting, NVIDIA, Moderna And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Nasdaq Composite gaining more 2% on Thursday. 
Via Benzinga
Topics Stocks
Could Novavax Stock Help You Become a Millionaire?
Novavax aims to win with its coronavirus/flu vaccine candidate, now in clinical trials. 
Via The Motley Fool
Looking Into Novavax's Recent Short Interest
 
Via Benzinga
Morgan Stanley Is Pounding the Table on DoorDash (DASH) Stock
DoorDash stock is rising higher on Thursday after Morgan Stanley upgraded DASH shares and increased their price target for them. 
Via InvestorPlace
Morgan Stanley Issues a Warning on Rivian (RIVN) Stock
Rivian stock is falling hard on Friday as RIVN investors react to a warning from Morgan Stanley and a weak EV production guidance for 2024. 
Via InvestorPlace
What's Going On With Novavax Stock Today?
Novavax said it reached a settlement with Gavi related to the 2021 advance purchase agreement for Novavax's prototype COVID-19 vaccine. The agreement brings the pending arbitration related to the... 
Via Benzinga
NVAX Stock Climbs as Novavax Settles Covid-19 Vaccine Dispute
Novavax stock is climbing higher on Thursday as investors in NVAX shares react to it reaching a $475 million settlement with Gavi. 
Via InvestorPlace
Get Rich Quick With These 3 Stocks to Buy Now
Although these market ideas are extremely speculative, their upcoming catalysts could make them stocks to buy now. 
Via InvestorPlace
Is It Too Late to Buy Novavax Stock?
The biotech could fade into irrelevance soon. 
Via The Motley Fool
Where Will Novavax Be in 5 Years?
Can the beaten-down stock turn things around? 
Via The Motley Fool
3 Doomed Biotech Stocks to Dump Before They Dive: February 2024
Spot the looming risks in the biotech sector and avoid these three doomed biotech stocks likely to burn shareholder value significantly. 
Via InvestorPlace
3 Beaten-Down Growth Stocks that Could Take off in the New Bull Market
Bull markets favor growth stocks so now could be the time for these players to shine. 
Via The Motley Fool
Novavax's Malaria Vaccine Gets WHO Prequalification, Has Potential Of Being An Affordable Option
Novavax's R21/Matrix-M malaria vaccine, with 75% efficacy in seasonal areas. Affordable at $3 per dose, it outshines GSK's vaccine. Global rollout expected mid-2024. 
Via Benzinga
Novavax Layoffs 2024: What to Know About the Latest NVAX Job Cuts
The Novavax layoffs are coming for 12% of the company's global workforce. However, NVAX stock itself could shock the market. 
Via InvestorPlace
Topics Workforce
3 Under-the-Radar Stocks With 340% to 762% Upside in 2024, According to Select Wall Street Analysts
If a trio of Wall Street analysts is correct, three lesser-known stocks could skyrocket in the new year. 
Via The Motley Fool
1 Reason to Buy Novavax Stock, and 3 (Better) Reasons to Sell
This biotech isn't at the end of the road just yet, but don't bet on a revival. 
Via The Motley Fool
1 Reason to Buy Novavax Stock Hand Over Fist and 1 Reason to Sell
The stock is high risk, but rewards could be great if all works out well for Novavax. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
64 65 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.